Canaccord Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB)

Canaccord analyst Edward Nash reiterated a Buy rating and $7.00 price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB).

The analyst commented: "Connect is currently conducting its Phase II Seabreeze STAT program with rademikibart for acute respiratory exacerbations (asthma or COPD attacks). Data readout is expected imminently, with Seabreeze STAT asthma expected in the first week of September and Seabreeze STAT COPD expected approximately two weeks later. We wanted to take a moment to review the program and our expectations for the data readout. We reiterate our BUY rating on shares of CNTB and our 12-month, $7 PT."

For an analyst ratings summary and ratings history on Connect Biopharma Holdings Ltd click here. For more ratings news on Connect Biopharma Holdings Ltd click here.

Shares of Connect Biopharma Holdings Ltd closed at $2.45 yesterday.

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• General Electric wins $2.9B Navy engine contract from DoD
• Cascadero Copper to sell subsidiary to Lumina Copper for up to $19M